PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Recombinant Protein and Antibody Laboratory, Copenhagen University Hospital, Copenhagen, Denmark.\', \'Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.\', \'Novo Nordisk A/S, Måløv, Denmark.\', \'Department of Biomedicine, Aarhus University, Århus, Denmark.\', \'Institute of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.\', \'Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.7554/eLife.70002e70002
?:hasPublicationType
?:journal
  • eLife
is ?:pmid of
?:pmid
?:pmid
  • 34821555
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 7.121
?:rankingScore_hIndex
  • 74
?:title
  • The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34821555>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34821555>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all